Diagnosis and Treatment of Pulmonary Hypertension : From Bench to Bedside /
This book focuses on pulmonary arterial hypertension (PAH, Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) among the various groups of pulmonary hypertension (PH) whose classification was updated into five major categories at the 5th World Symposium held in Nice, France,...
Saved in:
Corporate Authors: | |
---|---|
Group Author: | |
Published: |
Springer Singapore : Imprint: Springer,
|
Publisher Address: | Singapore : |
Publication Dates: | 2017. |
Literature type: | eBook |
Language: | English |
Subjects: | |
Online Access: |
http://dx.doi.org/10.1007/978-981-287-840-3 |
Summary: |
This book focuses on pulmonary arterial hypertension (PAH, Group 1) and chronic thromboembolic pulmonary hypertension (CTEPH, Group 4) among the various groups of pulmonary hypertension (PH) whose classification was updated into five major categories at the 5th World Symposium held in Nice, France, in 2013. Readers will find recent progress, methods, and up-to-date information on PH mechanisms, diagnostic images, and treatment in the management of PH. This volume, with contributions by leading researchers worldwide in the field , consists of five parts, starting with the fundamentals of PH, then pathophysiology and genetics, treatment, and right ventricular function. |
Carrier Form: | 1 online resource(VIII,236pages): illustrations |
ISBN: | 9789812878403 |
Index Number: | RC681 |
CLC: | R544.1 |
Contents: | Part I Fundamentals of Pulmonary Hypertension -- 1.Clinical Classification -- 2.Diagnosis Imagings -- Part II Pathophysiology and Genetics -- 3.Pathogenic and Therapeutic Role of MicroRNA in Pulmonary Arterial Hypertension -- 4.Sex Hormones -- 5.Rho-Kinase -- 6.The Unique Property of the Pulmonary Artery Regard-ing the Smooth Muscle Effects of Proteinase-activated Receptor 1 - The Possible Contribution to the Pathogenesis of Pulmonary Hypertension -- 7. Animal Models with Pulmonary Hypertension -- 8.Human Pathology -- 9. Pathophysiology and Genetics: BMPR2 -- Part III Treatment of Pulmonary Arterial Hypertension (PAH) -- 10. Prostacyclin -- 11. Targeting the NO-sGC-cGMP pathway in pulmonary arterial hypertension -- 12. Endothelin Receptor Antagonist -- 13. LUNG TRANSPLANTATION -- Part IV Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH) -- 14. Medical Therapy for Chronic Thromboembolic Pulmonary Hypertension -- 15. Balloon Pulmonary Angioplasty -- 16. Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension -- Part V Right Ventricular Function -- 17. Right Ventricular Function. |